Biotech CAR-T roundup: Autolus, Gracell tout early-stage data at ASH

SAN DIEGO — Big Pharma companies aren’t the only players at #ASH23. Many biotechs — including Autolus and Gracell — who are looking to make their mark in hematology and blood cancers are also here in California to present CAR-T treatment data.

Filed for approval, Autolus again expands its dataset

Click here to view original post